Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Oct;89(10):1123-1130.
doi: 10.1007/s00115-018-0585-2.

[Transition from neuropediatrics to neurology in neuromuscular diseases]

[Article in German]
Affiliations
Review

[Transition from neuropediatrics to neurology in neuromuscular diseases]

[Article in German]
U Schara et al. Nervenarzt. 2018 Oct.

Abstract

Background: Neuromuscular diseases in childhood, adolescence and adulthood are rare or very rare diseases and for many of them the prevalence and incidence are unknown. Causal therapies are currently used for individual disease entities only. Nevertheless, new genetic methods, a better understanding of the pathophysiology and multidisciplinary treatment concepts help to improve patient life expectancy and quality of life. As a result, more and more patients with an early disease onset reach adulthood and further care in adult medicine is necessary. This imposes new challenges particularly on neurology and the requirements for interdisciplinary cooperation in adult medicine are increased.

Objective: How can transition be made meaningful? Where do structural and content problems stand out?

Material and method: Using the example of Duchenne muscular dystrophy, the content and structural requirements for transition are presented and important aspects and possible problems are pointed out.

Conclusion: The transition process is complex and requires time and personnel resources. If carried out sensibly, it can lead to a better and more efficient care of patients in the long term and thus can also become economically more effective.

Keywords: Cardiology; Duchenne muscular dystrophy; Medication; Pneumology; Treatment concept.

PubMed Disclaimer

References

    1. Pediatr Transplant. 2013 Sep;17(6):518-24 - PubMed
    1. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2008 Jun;51(6):592-601 - PubMed
    1. Lancet Neurol. 2018 Mar;17(3):251-267 - PubMed
    1. Curr Opin Pediatr. 2001 Aug;13(4):310-6 - PubMed
    1. Pediatr Transplant. 2015 Nov;19(7):691-7 - PubMed